title: Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
abstract: The new diagnostic criteria for Alzheimer's disease (AD) acknowledges the interest given to biomarkers to improve the specificity in subjects with dementia and to facilitate an early diagnosis of the pathophysiological process of AD in the prodromal or pre-dementia stage. The current availability of PET imaging biomarkers of synaptic dysfunction (PET-FDG) and beta amyloid deposition using amyloid-PET provides clinicians with the opportunity to apply the new criteria and improve diagnostic accuracy in their clinical practice. Therefore, it seems essential for the scientific societies involved to use the new clinical diagnostic support tools to establish clear, evidence-based and agreed set of recommendations for their appropriate use. The present work includes a systematic review of the literature on the utility of FDG-PET and amyloid-PET for the diagnosis of AD and related neurodegenerative diseases that occur with dementia. Thus, we propose a series of recommendations agreed on by the Spanish Society of Nuclear Medicine and Spanish Society of Neurology as a consensus statement on the appropriate use of PET imaging biomarkers.
authors.affiliation: Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España. Electronic address: jarbizu@unav.es.
authors.forename: Javier
authors.initials: J
authors.lastname: Arbizu
authors.affiliation: Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: Guillermo
authors.initials: G
authors.lastname: García-Ribas
authors.affiliation: Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Ignasi
authors.initials: I
authors.lastname: Carrió
authors.affiliation: Servicio de Medicina Nuclear, Hospital San Pedro y Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, España.
authors.forename: Puy
authors.initials: P
authors.lastname: Garrastachu
authors.affiliation: Neurología Fundación CITA-Alzhéimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, España.
authors.forename: Pablo
authors.initials: P
authors.lastname: Martínez-Lage
authors.affiliation: Unidad de Enfermedad de Alzheimer y Otros Trastornos Cognitivos, Servicio de Neurología, Hospital Clinic i Universitari ICN y Fundación Pasqual Maragall, Barcelona, España.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Molinuevo
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging; D016229:Amyloid beta-Peptides / Q000032:analysis; D000814:Aniline Compounds; D015415:Biomarkers; D001923:Brain Chemistry; D002250:Carbon Radioisotopes; D003704:Dementia / Q000000981:diagnostic imaging*; D042241:Early Diagnosis; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D019636:Neurodegenerative Diseases / Q000000981:diagnostic imaging*; D059906:Neuroimaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D015415:Biomarkers; D002250:Carbon Radioisotopes; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18
keywords: (18)F-FDG; Alzheimer; Alzheimer's disease; Amyloid imaging; Biomarcadores PET; Demencia; Dementia; Deterioro cognitivo ligero; Enfermedad de Alzheimer prodrómica; Imagen amiloide; Mild cognitive impairment; PET imaging biomarkers; Prodromal Alzheimer disease